Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | RESILIENT: liposomal irinotecan in relapsed SCLC

David Spigel • 28 May 2020
ASCO 2020
Lung Cancer Small Cell Lung Cancer Irinotecan
RESILIENT

David R. Spigel, MD, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, discusses the ongoing phase III RESILIENT study (NCT03088813) which aims to evaluate the efficacy of liposomal irinotecan against standard topotecan therapy in relapsed small cell lung cancer (SCLC) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from David Spigel

2:00
Lung cancer updates at ASCO 2021
David Spigel • 26 May 2021
4:46
5-year survival outcomes from the PACIFIC trial
David Spigel • 26 May 2021
3:37
CANOPY-A: canakinumab for early stage NSCLC
David Spigel • 28 May 2020
4:58
Discussion on the ADAURA study
David Spigel • 28 May 2020

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals